Amiodarone Pharmacology

Mechanism of Action—Electrophysiologic Properties

Primary Class III Effect (Potassium Channel Blockade)

• Amiodarone's predominant mechanism involves blockade of voltage-gated potassium channels, prolonging the action potential duration (APD) and refractory period across all cardiac tissue
• This results in QT prolongation on the electrocardiogram, increasing the effective refractory period without significantly slowing conduction velocity
• Slows repolarization in both atria and ventricles, suppressing ectopic activity and reducing re-entry potential

Class I Effect (Sodium Channel Blockade)

• At higher concentrations and in acute settings, amiodarone inhibits fast sodium channels, slowing atrial and ventricular conduction velocity
• Decreases the slope of phase 0 depolarization, particularly in rapidly firing tissues
• Contributes to both antiarrhythmic and negative inotropic effects

Class II Effect (Beta-Adrenergic Blockade)

• Amiodarone possesses non-competitive beta-1 and beta-2 adrenergic blocking properties without the intrinsic sympathomimetic activity of traditional beta-blockers
• Slows AV nodal conduction and prolongs the AV nodal refractory period
• Reduces automaticity of ectopic pacemakers, particularly those with enhanced sympathetic tone
• Contributes to heart rate reduction and blood pressure lowering effects

Class IV Effect (Calcium Channel Blockade)

• Inhibition of L-type calcium channels in the AV node and sinoatrial (SA) node
• Further slows AV nodal conduction and prolongs the AV nodal refractory period
• Produces a negative inotropic effect, though this is partially offset by sympathomimetic properties

Molecular Structure and Unique Properties

• Amiodarone is a benzofuran derivative containing high iodine content (approximately 37% by weight)
• Highly lipophilic with extensive tissue distribution, particularly to adipose tissue, explaining its very long elimination half-life of 25-110 days
• Undergoes hepatic metabolism via the cytochrome P450 system (primarily CYP3A4 and CYP2C8), producing the active metabolite desethylamiodarone
• Exhibits non-linear pharmacokinetics, with steady-state levels achieved only after weeks to months of therapy

Indications for Amiodarone Use (Not technically "causes," but clinical contexts)

Ventricular Arrhythmias

• Ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) in cardiac arrest (ACLS protocol)
• Sustained monomorphic ventricular tachycardia with hemodynamic compromise or reduced ejection fraction
• Recurrent ventricular arrhythmias refractory to other agents or in patients who cannot tolerate beta-blockers/calcium channel blockers
• Post-myocardial infarction with reduced left ventricular ejection fraction (LVEF ≤40%) for primary prevention of sudden cardiac death
• Implantable cardioverter-defibrillator (ICD) storm management

Atrial Arrhythmias

• Atrial fibrillation, particularly in hemodynamically unstable patients or those with reduced ventricular function
• Atrial flutter (usually rate control is preferred)
• Maintenance of sinus rhythm post-cardioversion in paroxysmal or persistent atrial fibrillation

Risk Factors for Amiodarone Toxicity (Patient Selection)

• Underlying pulmonary disease (history of chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis)
• Thyroid dysfunction (history of hypothyroidism or hyperthyroidism, or iodine allergy)
• Hepatic impairment (cirrhosis, viral hepatitis, elevated transaminases)
• Renal disease (though amiodarone is not significantly renally cleared, metabolites may accumulate)
• Advanced age and comorbidities increase susceptibility to multiple adverse effects
• Concomitant medications that inhibit CYP3A4/CYP2C8 or have overlapping toxicity
• Prolonged QT interval at baseline (increased risk of torsades de pointes)

Intended Antiarrhythmic Effects (Beneficial)

Acute Administration (Intravenous)

• Rapid conversion of ventricular fibrillation to organized rhythm within minutes to hours
• Suppression of frequent premature ventricular contractions and ventricular tachycardia
• Rate control in rapid atrial fibrillation through AV nodal effects
• Hemodynamic stabilization in patients with arrhythmia-induced shock

Chronic Oral Administration

• Maintenance of sinus rhythm in patients with atrial fibrillation
• Reduction in arrhythmia recurrence rates and burden
• Gradual heart rate lowering and improved hemodynamic stability
• Reduced sudden cardiac death risk in high-risk populations

Adverse Effects—Organ Toxicity (Detrimental)

• Acute pneumonitis: Dyspnea, cough, fever, and malaise occurring within weeks to months of initiation
• Chronic interstitial pneumonitis/pulmonary fibrosis: Insidious progressive dyspnea, orthopnea, reduced exercise tolerance
• Pulmonary edema (non-cardiogenic) with acute respiratory distress
• Cough and chest discomfort as early warning signs
• Ground-glass opacities or interstitial infiltrates on chest imaging
• Hypoxemia and reduced diffusion capacity on pulmonary function testing (DLco)

• Hypothyroidism (more common): Fatigue, weight gain, constipation, bradycardia, dry skin, elevated TSH
• Thyrotoxicosis/Hyperthyroidism (less common but more severe): Palpitations, heat intolerance, weight loss, anxiety, tremor, suppressed TSH
• Due to amiodarone's high iodine content causing both iodine-induced hypothyroidism and thyroiditis-like thyrotoxicosis

• Asymptomatic elevation of transaminases (transient, seen in 25% of patients)
• Acute hepatitis: Jaundice, right upper quadrant pain, hepatomegaly, elevated ALT/AST
• Cirrhosis and hepatic failure (rare but potentially fatal)
• Phospholipidosis on histology (lipid accumulation in hepatocytes)

• Corneal microdeposits (keratopathy): Asymptomatic brown/gray deposits in cornea affecting 90-100% of chronic users
• Blurred vision or halos around lights in photopic conditions
• Optic neuritis/neuropathy: Reduced visual acuity and color vision, particularly affecting yellow-blue discrimination (rare but serious)
• Deposits may take months to years to resolve after discontinuation

• Photosensitivity reactions: Severe sunburns with minimal sun exposure
• Blue-gray skin discoloration (slate-gray pigmentation, particularly in sun-exposed areas)
• Rashes and dermatitis

Neurologic Toxicity

• Tremor, ataxia, gait disturbance, peripheral neuropathy
• Headache, dizziness, confusion
• Sleep disturbances and nightmares

• Negative inotropism leading to worsening heart failure in susceptible patients
• Bradycardia and sinus node dysfunction (contraindicated in sick sinus syndrome without pacemaker)
• QT prolongation with potential for torsades de pointes (though amiodarone paradoxically has a lower proarrhythmic risk than other Class III agents despite QT prolongation)
• Hypotension (particularly with IV administration)

Drug Interactions and Medication Effects

• Increased risk of bleeding with warfarin (amiodarone inhibits CYP2C9)
• Bradycardia and AV block with concurrent beta-blockers or calcium channel blockers
• Increased risk of torsades de pointes with QT-prolonging drugs (macrolides, fluoroquinolones, antipsychotics)
• Elevated levels of digoxin, metoprolol, propranolol, diltiazem, verapamil (CYP3A4 inhibition)
• Increased statin-induced myopathy (particularly simvastatin and lovastatin)

Diagnostic Approach to Confirm Indication for Amiodarone (Not diagnosis of amiodarone itself)

Electrocardiographic Assessment

• 12-lead ECG showing the specific arrhythmia: VT, VF, atrial fibrillation, atrial flutter, or other tachyarrhythmia requiring suppression
• Baseline QTc interval measurement (normal <450 ms in men, <460 ms in women); amiodarone should be avoided if baseline QTc >500 ms due to proarrhythmic risk
• PR interval, QRS duration, and QT interval serve as baseline parameters for monitoring during therapy
• Amiodarone produces characteristic ECG changes: QT prolongation, bradycardia, PR prolongation, and reduced QRS amplitude

Monitoring for Amiodarone Toxicity

Laboratory Assessment (Baseline and Periodic)

• TSH and free T4 before initiation, at 6 months, then annually (or if symptoms develop)
• Interpretation: TSH >4.5 mIU/L indicates hypothyroidism; TSH <0.1 mIU/L with elevated free T4 indicates thyrotoxicosis
• More frequent monitoring (every 3 months) in patients with risk factors

• Baseline AST, ALT, alkaline phosphatase, bilirubin
• Repeat at 6 months, then annually or if clinical suspicion for hepatotoxicity
• Asymptomatic elevation of transaminases (typically <3× upper limit of normal) is common and may not warrant discontinuation
• AST/ALT >3× normal warrants further investigation and possible discontinuation

• Baseline serum creatinine and estimated glomerular filtration rate (eGFR)
• Periodic monitoring (6-12 months) as amiodarone may accumulate in renal disease
• Though amiodarone undergoes minimal renal excretion, desethylamiodarone metabolite accumulates

• Baseline ophthalmologic examination including dilated fundoscopy and color vision testing (Ishihara or similar)
• Annual or biennial formal eye exams during chronic therapy
• More frequent if visual symptoms develop

Pulmonary Assessment (Critical Given Toxicity Risk)

• Clinical history of pulmonary disease, smoking history, occupational exposures
• Chest X-ray (CXR) baseline to assess for interstitial disease
• Pulmonary function tests (PFTs): Baseline FVC, FEV1, DLco (diffusion capacity is the most sensitive indicator of amiodarone-induced pulmonary toxicity)
• High-resolution CT (HRCT) chest if any baseline abnormalities or high suspicion for occult disease

• Repeat CXR at 6-12 months, then as clinically indicated
• Repeat PFTs (particularly DLco) annually; a decline in DLco >15% or FVC >10% is concerning for amiodarone-induced pneumonitis
• Lower threshold for imaging if patient develops respiratory symptoms (dyspnea, cough, fever)

Amiodarone Plasma Levels

• Therapeutic range: 1-2.5 μg/mL (some sources cite 1-3 μg/mL)
• Levels drawn at steady state (after 5-7 days of IV therapy or 5-7 weeks of oral therapy) are most reliable
• Due to variable metabolism and distribution, routine level monitoring is not recommended for dose adjustments
• Clinical response and adverse effects are better guides than plasma levels

Treatment Strategy: Indication-Based Administration

Acute Management of Life-Threatening Arrhythmias (Intravenous Amiodarone)

• Loading dose: 300 mg IV bolus diluted in 20-30 mL normal saline administered rapidly via peripheral IV or central line
• Repeat dose: 150 mg IV at 10-15 minute intervals (after defibrillation attempts and CPR)
• Maximum cumulative dose: 2.2 g per 24 hours
• Mechanism: Sodium and potassium channel blockade along with beta-blockade provide antiarrhythmic effect without requiring IV access challenges or hemodynamic monitoring of traditional alternatives

• Loading regimen: 150 mg IV bolus over 10 minutes
• Second dose (optional): 150 mg IV over 10 minutes if arrhythmia persists
• Maintenance infusion: 0.5-1.0 mg/min for 6 hours, then reduce to 0.5 mg/min for next 18 hours
• Monitor for hypotension, bradycardia, and prolonging PR/QT intervals

• Central line preferred for concentrations >2 mg/mL due to phlebitis risk with peripheral administration
• Dilute in normal saline or 5% dextrose (never use normal saline for concentrations >2 mg/mL in peripheral lines due to irritation)
• Infuse slowly to minimize hypotension and thrombophlebitis
• Incompatible with many medications; establish separate IV line when possible

Chronic Oral Amiodarone Therapy (Ventricular and Atrial Arrhythmias)

• High-dose loading: 600-800 mg daily (divided doses) for 1-3 weeks
• Alternative: 10 g total over 1-2 weeks (e.g., 1200 mg daily × 5 days, then 600 mg daily × 5 days, then 400 mg daily × 3 days)
• Goal is to achieve steady-state levels and suppress arrhythmia while establishing baseline organ function

• Standard maintenance: 200-400 mg daily (most commonly 200-300 mg daily)
• Dose reduced to lowest effective dose to minimize cumulative toxicity
• Many patients require only 100-200 mg daily for maintenance after initial loading
• Titrate based on arrhythmia control and adverse effects

Mechanisms behind the classic toxicities

• Pulmonary toxicity: the lipophilic drug concentrates in alveolar macrophages and type II pneumocytes, inhibiting lysosomal phospholipase A and producing phospholipidosis (foamy macrophages); direct oxidant injury plus a hypersensitivity component drives pneumonitis progressing to fibrosis. It is the most feared toxicity and the leading cause of amiodarone-related death.
• Thyroid dysfunction: each 200 mg tablet liberates far more iodide than the daily requirement. Iodine excess causes hypothyroidism via Wolff–Chaikoff escape failure, while Jod–Basedow phenomenon (type 1 amiodarone-induced thyrotoxicosis, in nodular goiter/latent Graves) or destructive thyroiditis (type 2) causes hyperthyroidism. Amiodarone also blocks type 1 5′-deiodinase, so a euthyroid patient can show high free T4, low T3, and mildly high TSH — a common trap.
• Hepatic injury: phospholipidosis and mitochondrial injury; transaminase elevation is common and often benign, but progressive hepatitis or cirrhosis mandates withdrawal.
• Ocular deposits: iodine-containing drug–lipid complexes in corneal epithelium (whorl-like keratopathy); optic neuropathy is rare but requires immediate discontinuation.
• Dermatologic: photosensitivity from phototoxic free-radical generation; dermal lipofuscin/drug deposition gives slate-gray "blue man" discoloration.
• Neuropathy/tremor: axonal and demyelinating injury, dose- and duration-dependent.

Contraindications and cautions

• Absolute/relative contraindications: cardiogenic shock, marked sinus bradycardia or sick sinus syndrome, and second- or third-degree AV block without a functioning pacemaker; iodine hypersensitivity; pregnancy (fetal goiter/hypothyroidism, growth restriction).
• Excipient effects: IV hypotension reflects the vasodilatory vehicle (polysorbate 80/benzyl alcohol) as much as the drug itself — slow the infusion rather than abandoning the agent.
• Interactions: reduce warfarin and digoxin doses empirically when amiodarone is started, and avoid high-dose simvastatin/lovastatin (myopathy).

Reversal and treatment

• No specific antidote exists; the enormous volume of distribution and multi-week half-life mean toxicity persists for months after stopping, and the drug is not dialyzable.
• Pneumonitis: discontinue and give systemic corticosteroids (prednisone) for significant disease.
• Thyroid disease: levothyroxine for hypothyroidism (amiodarone may be continued); per the American Thyroid Association, thionamides (methimazole) for type 1 thyrotoxicosis and glucocorticoids for type 2, with mixed/unclear cases often treated with both.

• Cardiac arrest dosing is the single most tested number: for shockable rhythms — ventricular fibrillation and pulseless ventricular tachycardia — AHA ACLS gives amiodarone 300 mg IV/IO push after failed defibrillation and epinephrine, then 150 mg for a second dose. Lidocaine is an acceptable alternative; amiodarone is not used for asystole or PEA.
• New dyspnea plus dry cough in a patient on chronic amiodarone: the single best next step is chest imaging (CXR, then HRCT) with pulmonary function testing including DLco, and stopping the drug. Do not anchor on heart failure exacerbation just because the patient has cardiomyopathy.
• Abnormal thyroid tests are the most commonly tested association. Order TSH first; hypothyroidism is more common overall and is treated with levothyroxine without stopping amiodarone. An isolated high free T4 with low T3 in an asymptomatic patient is deiodinase inhibition, not thyrotoxicosis.
• Classic buzzwords: corneal microdeposits (near-universal, usually asymptomatic, not an indication to stop), slate-gray/blue-gray photodistributed skin discoloration, foamy macrophages/phospholipidosis, and half-life measured in weeks to months.
• QT prolongation without much torsades: amiodarone prolongs the QT interval in essentially everyone yet has a strikingly low proarrhythmic rate compared with sotalol, dofetilide, or ibutilide because it blocks multiple channels and shortens transmural dispersion of repolarization. Do not reflexively stop it for QT prolongation alone.
• It is the antiarrhythmic of choice when the ventricle is sick: unlike class IC agents (contraindicated after MI and in structural disease, per the ACC/AHA arrhythmia guidelines and the CAST experience), amiodarone is comparatively safe in reduced ejection fraction.
• Common distractor — amiodarone is not a mortality drug: in SCD-HeFT it did not improve survival versus placebo, whereas the ICD did. Amiodarone suppresses arrhythmia and reduces ICD shocks; it does not substitute for a defibrillator.
• Do not confuse it with dronedarone, the deiodinated analog with less thyroid/pulmonary toxicity but which is contraindicated in decompensated heart failure and permanent atrial fibrillation.